Local Institution

Omaha, Nebraska 68114

0 studies enrolling now · 15 studies all time

What they study most

Breast Cancer, Chronic Myeloid Leukemia, Congestive Heart Failure, Diabetes Mellitus, Diabetes Mellitus II, Diabetes Mellitus, Type 2, Hypertension, Leukemia, Metastases, Multiple Myeloma, Philadelphia-Positive Myeloid Leukemia, Rheumatoid Arthritis

Studies at this site

• Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer — Completed
• Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" — Completed
• A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma — Completed
• Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone — Completed
• Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) — Completed
• Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise — Completed
• PPAR - Combination With Metformin — Completed
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib — Completed
• Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy — Completed
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension — Completed
• A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics — Completed
• Dose Ranging Study With LT, Monotherapy, PPAR — Completed
• Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone — Completed
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia — Completed
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy — Stopped early